Codeine is a prodrug: it must be bio-activated by the liver enzyme CYP2D6 into morphine before it can relieve pain, and how much morphine forms depends entirely on a patient's CYP2D6 genotype. This simulator renders that activation pathway in 3D — codeine molecules travel from the gut into a CYP2D6 enzyme zone in the liver, where each one is either converted to morphine and released toward a CNS effect site, or cleared unconverted through other metabolic routes, with the odds set by the selected genotype's activity score. A parallel one-compartment pharmacokinetic model drives live plasma-level readouts and a real-time concentration chart, so switching between Poor, Intermediate, Normal and Ultra-rapid Metabolizer shows the same oral dose swing from therapeutic failure, to normal analgesia, to a documented toxicity risk — the exact mechanism behind codeine's contraindication in children and breastfeeding mothers with the ultra-rapid phenotype.